ALGS Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Aligos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.20 |
| 52 Week High | US$30.00 |
| 52 Week Low | US$6.76 |
| Beta | 2.12 |
| 11 Month Change | 149.66% |
| 3 Month Change | 31.50% |
| 1 Year Change | 7.06% |
| 33 Year Change | -95.53% |
| 5 Year Change | n/a |
| Change since IPO | -95.10% |
Recent News & Updates
Recent updates
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry
Jul 31
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely
Jul 16Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues
May 24Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Apr 09Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues
Feb 23Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 24We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Jul 17We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully
Mar 11Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B
Jul 25We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Jul 11We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate
Feb 02Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation
Oct 19Aligos Therapeutics EPS beats by $0.16
May 10We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely
May 01What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?
Jan 16Shareholder Returns
| ALGS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | -6.5% | -1.0% |
| 1Y | 7.1% | 14.6% | 30.3% |
Return vs Industry: ALGS underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: ALGS underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| ALGS volatility | |
|---|---|
| ALGS Average Weekly Movement | 26.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ALGS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALGS's weekly volatility has increased from 17% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 68 | Larry Blatt | www.aligos.com |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
Aligos Therapeutics, Inc. Fundamentals Summary
| ALGS fundamental statistics | |
|---|---|
| Market cap | US$68.66m |
| Earnings (TTM) | -US$76.95m |
| Revenue (TTM) | US$6.00m |
11.3x
P/S Ratio-0.9x
P/E RatioIs ALGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALGS income statement (TTM) | |
|---|---|
| Revenue | US$6.00m |
| Cost of Revenue | US$76.50m |
| Gross Profit | -US$70.50m |
| Other Expenses | US$6.46m |
| Earnings | -US$76.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -20.73 |
| Gross Margin | -1,175.55% |
| Net Profit Margin | -1,283.19% |
| Debt/Equity Ratio | 0% |
How did ALGS perform over the long term?
See historical performance and comparison